Repotrectinib
Sign in to save this workspacePrimary targets: ROS_ROS1 · FDA status: FDA Approved
Selectivity scorecard
KISS
84.21
Gini
0.608
CATDS
0.008
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Repotrectinib. Strongest target: ROS_ROS1 at 100.0% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | ROS_ROS1 | 100.0% | 0.0% |
| 2 | TRKB | 99.8% | 0.2% |
| 3 | TXK | 99.8% | 0.2% |
| 4 | EPHA2 | 99.6% | 0.4% |
| 5 | ALK | 99.4% | 0.6% |
| 6 | BMX_ETK | 99.3% | 0.7% |
| 7 | DDR1 | 99.3% | 0.7% |
| 8 | FAK_PTK2 | 99.2% | 0.8% |
| 9 | ACK1 | 99.0% | 1.0% |
| 10 | TRKA | 98.9% | 1.1% |
| 11 | TRKC | 98.9% | 1.1% |
| 12 | FGR | 98.9% | 1.1% |
| 13 | LYN | 98.7% | 1.3% |
| 14 | MUSK | 98.6% | 1.4% |
| 15 | LCK | 98.6% | 1.4% |
| 16 | YES_YES1 | 98.4% | 1.6% |
| 17 | BLK | 98.4% | 1.6% |
| 18 | JAK2 | 98.3% | 1.7% |
| 19 | DDR2 | 98.3% | 1.8% |
| 20 | EPHB4 | 98.2% | 1.8% |
Selectivity landscape
Where Repotrectinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Repotrectinib.
Annotations
Sign in to read and post annotations.
Loading…